Literature DB >> 15653345

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

Hailin Zheng1, Lev M Weiner, Orit Bar-Am, Silvina Epsztejn, Z Ioav Cabantchik, Abraham Warshawsky, Moussa B H Youdim, Mati Fridkin.   

Abstract

Several novel antioxidant-iron chelators bearing 8-hydroxyoxyquinoline moiety were synthesized, and various properties related to their iron chelation, and neuroprotective action were investigated. All the chelators exhibited strong iron(III) chelating and high antioxidant properties. Chelator 9 (HLA20), having good permeability into K562 cells and moderate selective MAO-B inhibitory activity (IC50 110 microM), displayed the hightest protective effects against differentiated P19 cell death induced by 6-hydroxydopamine. EPR studies suggested that Chelator 9 also act as radical scavenger to directly scavenge hydroxyl radical.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15653345     DOI： 10.1016/j.bmc.2004.10.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  56 in total

1.  Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Authors:  Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

2.  Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Authors:  Hailin Zheng; Moussa B H Youdim; Mati Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-10-04       Impact factor: 4.418

3.  Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurochem Res       Date:  2007-08-12       Impact factor: 3.996

Review 4.  Iron homeostasis and eye disease.

Authors:  Allison Loh; Majda Hadziahmetovic; Joshua L Dunaief
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 5.  Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Authors:  Cornelis J Van der Schyf; Werner J Geldenhuys
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 6.  Transcriptional regulation and multiple functions of MAO genes.

Authors:  Jean C Shih; Jason Boyang Wu; Kevin Chen
Journal:  J Neural Transm (Vienna)       Date:  2011-02-27       Impact factor: 3.575

Review 7.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

8.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

9.  Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice.

Authors:  Lana Kupershmidt; Tamar Amit; Orit Bar-Am; Orly Weinreb; Moussa B H Youdim
Journal:  Mol Neurobiol       Date:  2012-07-31       Impact factor: 5.590

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.